Procedure for assessing the acceptability, in principle, of vaccines ...

Geneva, Switzerland; Dr U Rosskopf, World Health Organization, Geneva,
Switzerland.
The proposals were discussed at the "Informal consultation with the ad hoc committee
on vaccines prequalification for the revision of the procedure for assessing the
acceptability, in principle, of vaccines for purchase by UN agencies" and
recommendations were received from the ad hoc committee members – Ms LG
Castanheira, ANVISA, Brasilia, Brazil; Dr P Chagnaud, Agence Française de Sécurite
Sanitaire de Produits de Santé, Lyon, France; Ms X Chen, State Food and Drug
Administration, Beijing, People's Republic of China; Dr E Cooke, European
Medicines Agency, London, England; Dr R Dobbelaer, Lokeren, Belgium; Mr RD
Morales, Centro Control Estatal de la Calidad de los Medicamentos, Havana, Cuba;
Dr M Eisenhawer, Swiss Agency for Therapeutic Products Inspectorates, Bern,
Switzerland; Dr I Feavers, National Institute for Biological Standards and Control,
Potters Bar, England; Dr M Ferguson, Independent, Norfolk, England; Ms T
Jivapaisarnpong, Ministry of Public Health, Bangkok, Thailand; Dr J Joung, Korea
Food and Drug Administration, Seoul, Republic of Korea; Dr R Nibbeling, National
Institute of Public Health and Environment Protection, Bilthoven, Netherlands; Dr M-
H Pinheiro, European Medicines Agency, London, England; Prof H Rees, University
of the Witwatersrand, Johannesburg, South Africa; Dr. C Rolls, Therapeutic Goods
Administration, Woden ACT, Australia; Dr VG Somani, Ministry of Health and
Central Drugs Standard Control Organisation, New Delhi, India; Dr L Slamet,
National Agency of Food and Drug Control, Jakarta, Indonesia; Dr J Southern,
Temporary Adviser, Pretoria, South Africa; Dr JM Spieser, European Pharmacopoeia
Commission Secretariat, Strasbourg, France; Dr L Tesolin, Scientific Institute of
Public Health, Brussels, Belgium; Dr W Vergeer, National Control Laboratory,
Bloemfontein, South Africa; Dr JW Blair, US Food and Drug Administration,
Rockville, MD, USA; Dr K Midthun, Center for Biologics Evaluation and Research,
Rockville, MD, USA and other meeting participants.
The first draft of the revised procedure was prepared by the drafting group: Ms E
Uramis, Consultant, World Health Organization, Geneva, Switzerland; Dr N
Dellepiane, World Health Organization, Geneva, Switzerland; Dr D Meek, World
Health Organization, Geneva, Switzerland; Ms C Rodriguez, World Health
41